Summary

The Joint Program for Molecular Diagnostics of Cancer between the IGTP* and the ICO aims to combine efforts and resources to offer an integrated program focused on the study of hereditary and familial cancers. In the program genetic diagnostics, basic and applied research will be closely coordinated.

This program will collaborate with the Genetic Counseling Program and the Genetic Epidemiology of Cancer Program.

Our Research

Organization of the Program

        

The ICO-IDIBELL-IGTP Joint Program for Molecular Diagnostics of Hereditary Cancer is co-directed by Dr Gabriel Capellà (ICO) and Dr Manuel Perucho (PMPPC at the IGTP).

The Program consists of three conceptually different units

The Genetic Diagnostics Unit concentrates on screening and detection of mutations and other genetic variations involved in hereditary cancers. It also uses a wide range of functional approaches to improve screening for and interpretation of the genetic alterations detected.

The Methodological and Technological Transfer Unit aims to develop and set up new tools and methodologies to improve screening, detection and interpretation of mutations or other genetic changes found in the genes governing hereditary cancers. This unit will respond to needs arising in the Genetic Diagnostics Unit due to advances in technology or methodology, whether they concern the genetic, molecular or cellular aspects.

The Research Unit will carry out research into aspects related to different hereditary cancers and the tumors that patients present.

Activities of the Program

The activities of the three units in the Joint Program are complementary and will focus on hereditary cancers, such as colorectal and breast amongst others.

Collaborations with other Programs

The Joint Program for Molecular Diagnostics of Cancer between the IGTP and the ICO works closely with the Genetic Counseling Program (ICO) and the Genetic Epidemiology Program all within the Hereditary Cancer Group.
The main objective of the Genetic Counseling Program is to work to reduce the impact of cancer by identifying individuals and families with increased risk of developing cancer and the implementation of adequate prevention measures in each case. It is an integrated program which combines attending to clinical and psychosocial needs of the patient and family with clinical research and training. It guarantees equal access to its services throughout the region.

The Genetic Epidemiology Program carries out studies at population level to better understand how genetic variation in individuals predisposes them to develop cancer, taking into account biological and environmental causes.

This close relation between programs ensures that the Hereditary Cancer Group provides a fully multidisciplinary approach to hereditary and familial cancer.

 

* The Joint Program was previously between the ICO-IDIBELL and the IMPPC.  The IMPPC now forms part of the Germans Trias i Pujol Research Institute (IGTP) as the Program for Predictive and Personalized Medicine of Cancer (PMPPC).


Contacte

At the IGTP
Eduard Serra
(+34) 93 554 30 67


Publicacions rellevants

Castellanos E, Gel B, Rosas I, Tornero E, Santín S, Pluvinet R, Velasco J, Sumoy L, Del Valle J, Perucho M, Blanco I, Navarro M, Brunet J, Pineda M, Feliubadaló L, Capellà G, Lázaro C, Serra E. A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape. Sci Rep 2017 Jan; 7: 39348

Feliubadaló L, Tonda R, Gausachs M, Trotta JR, Castellanos E, Lopez-Doriga A, Teulé A, Tornero E, Del Valle J, Gel B, Gut M, Pineda M, González S, Menéndez M, Navarro M, Capellà G, Gut I, Serra E, Brunet J, Beltran S, Lázaro C. Benchmarking of Whole Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of Hereditary Cancer. Sci Rep 2017 Jan; 7: 37984

Gel B, Díez-Villanueva A, Serra E, Buschbeck M, Peinado MA, Malinverni R. regioneR: an R/Bioconductor package for the association analysis of genomic regions based on permutation tests. Bioinformatics 2016 Jan; 32(2): 289-91

Castellanos E, Bielsa I, Carrato C, Rosas I, Solanes A, Hostalot C, Amilibia E, Prades J, Roca-Ribas F, Lázaro C, Blanco I, Serra E. Segmental neurofibromatosis type 2: discriminating two hit from four hit in a patient presenting multiple schwannomas confined to one limb. BMC Med Genomics 2015 Jan; 8: 2

Castellsagué J, Gel B, Fernández-Rodríguez J, Llatjós R, Blanco I, Benavente Y, Pérez-Sidelnikova D, García-Del Muro J, Viñals JM, Vidal A, Valdés-Mas R, Terribas E, Lopez-Doriga A, Pujana MA, Capellà G, Puente XS, Serra E, Villanueva A, Lázaro C. Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine. EMBO Mol Med 2015 Mar; 7(5): 608-27

Feliubadaló L, Lopez-Doriga A, Castellsagué E, Del Valle J, Menéndez M, Tornero E, Montes E, Cuesta R, Gómez C, Campos O, Pineda M, González S, Moreno V, Brunet J, Blanco I, Serra E, Capellà G, Lázaro C. Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes. Eur. J. Hum. Genet. 2013 Aug; 21(8): 864-70

Rahrmann EP, Watson AL, Keng VW, Choi K, Moriarity BS, Beckmann DA, Wolf NK, Sarver A, Collins MH, Moertel CL, Wallace MR, Gel B, Serra E, Ratner N, Largaespada DA. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat. Genet. 2013 Jul; 45(7): 756-66

Gomez-Sanchez JA, Gomis-Coloma C, Morenilla-Palao C, Peiro G, Serra E, Serrano M, Cabedo H. Epigenetic induction of the Ink4a/Arf locus prevents Schwann cell overproliferation during nerve regeneration and after tumorigenic challenge. Brain 2013 Jul; 136: 2262-78

Castellanos E, Rosas I, Solanes A, Bielsa I, Lázaro C, Carrato C, Hostalot C, Prades P, Roca-Ribas F, Blanco I, Serra E. In vitro antisense therapeutics for a deep intronic mutation causing Neurofibromatosis type 2. Eur. J. Hum. Genet. 2013 Jul; 21(7): 769-73

Terribas E, Garcia-Linares C, Lázaro C, Serra E. Probe-based quantitative PCR assay for detecting constitutional and somatic deletions in the NF1 gene: application to genetic testing and tumor analysis. Clin. Chem. 2013 Jun; 59(6): 928-37


Veure-les totes

Generalitat de Catalunya

Unió Europea

CSIC

Universitat Autònoma de Barcelona

Ajuntament de Badalona

Institut Català de la Salut

Germans Trias i Pujol Hospital

Fundació Institut d'investigació en Ciències de la Salut Germans Trias i Pujol

Back to Top